Lemtrada's Deadly Side Effects Greater Than Previously Thought

Lemtrada Stroke Lawsuit News

Ten previously unknown reports have been uncovered showing Lemtrada fatalities

Monday, September 2, 2019 - Multiple Sclerosis News Today, a leading online publication in their field has reported that a European study claims that anti-ms drug Lemtrada is more deadly to patients than originally thought. The study published in BMC Research Notes claims "Sporadic fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab, and deaths appear to be occurring more frequently than originally thought." The study queried the European Medicines Agency database for deaths that may have been caused by (alemtuzumab) a.k.a., Lemtrada and the results were analyzed and confirmed by medical experts. Ten were reported that occurred within one month of Lemtrada infusion that probably were caused by Lemtrada. Deaths occurred from "intracerebral hemorrhage, two from acute multiple organ failure and septic shock, one from listeriosis, one from pneumonia and one from agranulocytosis." The others died from auto-immune complications and infections attributed to Lemtrada.

Multiple Sclerosis New concluding that the number of deaths attributed to Lemtrada is higher than previously thought is more evidence that Lemtrada should be considered only as a drug of last resort. The Food and Drug Administration has warned that Lemtrada has been associated with causing life-threatening strokes and heart attacks. Doctors administering Lemtrada are required to monitor patients before, during and after Lemtrada infusions for any sign of a stroke or heart attack.

Anti MS drug Lemtrada, (alemtuzumab) is a type of protein called a monoclonal antibody that attaches to the CD52 protein in white blood cells, the building blocks of the human immune system, causing them to die and be replaced. Lemtrada is administered once per year in a two-day treatment by IV drip. Relapse-Remitting Multiple Sclerosis (RRMS) patients report having intermittent attacks followed by a period of remission. Lemtrada both lessens the severity of the attacks and extends the periods of remission. Lemtrada is the most effective drug on the market for alleviating the symptoms of Relapse Remitting Multiple Sclerosis, but the benefits of the drug come at a high cost. RRMS patients have experienced strokes within 24-hours of receiving their annual Lemtrada drip infusion. The list of potential adverse side effects caused by Lemtrada also include infections, auto-immune impairment, hemorrhaging, anemia, and necrotizing leukoencephalopathy.

Sanofi, maker of Lemtrada may have failed to warn patients of the risks of taking the drug. Lemtrada patients have reported strokes and arterial dissection. Patients that have suffered strokes and the loved ones of those that have died from taking Lemtrada may wish to consult with a Lemtrada attorney and file a claim for monetary damages. Over 20,000 patients have been injured by Lemtrada's side effects since the drug's FDA approval. Sanofi has finally acknowledged Lemtrada's side effects and has been required to post a warning on their website advising doctors and patients that the drug is to be used only when all other options have been exhausted.

More Recent Lemtrada Stroke Lawsuit News:

No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.